BioAge Labs, Inc. (NASDAQ:BIOA) Given Average Rating of “Moderate Buy” by Analysts

BioAge Labs, Inc. (NASDAQ:BIOA) has received an average recommendation of “Moderate Buy” from the seven research firms that are covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $36.5714.

A number of research firms recently issued reports on BIOA. Roth Capital reiterated a “buy” rating and set a $25.00 price objective on shares of BioAge Labs in a research note on Friday, July 31st. Wall Street Zen downgraded BioAge Labs from a “sell” rating to a “strong sell” rating in a research report on Saturday. Weiss Ratings reissued a “sell (d-)” rating on shares of BioAge Labs in a research note on Tuesday, July 21st. BTIG Research restated a “buy” rating and set a $40.00 target price on shares of BioAge Labs in a research report on Monday, August 3rd. Finally, Needham & Company LLC decreased their target price on BioAge Labs from $50.00 to $35.00 and set a “buy” rating on the stock in a research note on Friday, July 31st.

Hedge Funds Weigh In On BioAge Labs

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Geode Capital Management LLC increased its holdings in shares of BioAge Labs by 60.8% in the 2nd quarter. Geode Capital Management LLC now owns 453,455 shares of the company’s stock worth $1,873,000 after buying an additional 171,426 shares during the last quarter. Walleye Capital LLC bought a new stake in shares of BioAge Labs during the 2nd quarter worth $64,000. Marshall Wace LLP grew its position in BioAge Labs by 324.7% in the second quarter. Marshall Wace LLP now owns 226,789 shares of the company’s stock worth $937,000 after acquiring an additional 173,388 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in BioAge Labs by 85.6% in the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,955 shares of the company’s stock worth $54,000 after acquiring an additional 5,976 shares in the last quarter. Finally, Ameriprise Financial Inc. bought a new position in BioAge Labs in the second quarter valued at $182,000.

BioAge Labs Trading Up 0.9%

Shares of NASDAQ BIOA opened at $9.59 on Friday. The stock has a fifty day simple moving average of $16.50 and a two-hundred day simple moving average of $17.82. BioAge Labs has a 1-year low of $4.58 and a 1-year high of $25.95. The firm has a market cap of $440.18 million, a price-to-earnings ratio of -4.03 and a beta of 0.94.

BioAge Labs (NASDAQ:BIOA) last issued its earnings results on Wednesday, August 5th. The company reported ($0.58) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.65) by $0.07. The firm had revenue of $2.45 million during the quarter. BioAge Labs had a negative net margin of 912.26% and a negative return on equity of 28.99%. Analysts forecast that BioAge Labs will post -2.45 EPS for the current year.

About BioAge Labs

BioAge Labs (NASDAQ: BIOA) is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.